Codexis Inc (CDXS) Operatsion marja

Codexis Bio (CDXS) - korporativ logo

Codexis, Inc. (CDXS) fermentlar ishlab chiqishda yetakchilik qilgan holda, RNA terapevtikasi va yashil kimyo uchun ECO Synthesis texnologiyasini rivojlantirmoqda. Operatsion marja farqi ushbu strategiyaning samaradorligini tasdiqlaydi, bunda ko'rsatkich qiymati -14.40 ga yetadi. Biznes sarflanadigan materiallar va litsenziyalar sotuviga tayanib, barqaror FCF generatsiya qiladi. Barqarorlik esa aksiyalar opsionlari orqali saqlab qolingan protein muhandislari kuchli jamoasi tomonidan ta'minlanadi.

CDXS - Codexis Bio Operatsion foyda bo'yicha sotuv rentabelligi 04.07.2022 - 19.11.2026 oraligʻida

Codexis Bio (CDXS) kompaniyasining tahliliy kesimlari

- aksiya narxi va baholash bo'yicha konsensus prognoz:
- bozor kapitallashuvi tafsilotlari:
Kompaniyaning umumiy tahlili:codexis.com, CDXS
Codexis Inc tayyor mahsulotlari

CodeEvolver platformasidan va katalizatorlarga bo'lgan elastik bo'lmagan talabdan foydalanib, Codexis, Inc. (CDXS) o'zining texnologik noyobligini samarali monetizatsiya qilmoqda. Ushbu operatsion marja tushumni foizlar va soliqlar to'lovigacha bo'lgan foydaga aylantirish samaradorligini miqdoriy baholaydi. Mazkur ko'rsatkich moliyaviy leverajning ta'sirini hisobga olmagan holda, biznes modelining ichki samaradorligini o'lchaydi. Ushbu indikatorning o'sishi emitentning narxlarni belgilash quvvatini tasdiqlaydi. Operatsion marjani tahlil qilish mahalliy ekstremumlarda haddan tashqari ko'p to'lov qilishning oldini olishga yordam beradi.

Asosiy raqobatchilar

Sotuvning operatsion marjasi TEM|QGEN - Operatsion foyda bo'yicha marjinallik|Operatsion marja IONS|RGEN - Sotuvning operatsion rentabelligi|Operatsion rentabellik Avidity RNA|Operatsion marja CRISPR Therapeutics Corp CRSP|GeneDx Corp - Operatsion marja|Ultragenyx Pharma (RARE) - Sotuvning operatsion marjasi|beamtx.com (BEAM) - Operatsion rentabellik|SRPT: Operatsion foyda koeffitsiyenti|Sotuvning operatsion marjasi TWST|TXG - Operatsion foyda bo'yicha marjinallik|Operatsion marja NTLA|Operatsion faoliyat rentabelligi Stoke Therapeutics|Operatsion rentabellik BioLife Solutions BLFS|Wave Life Sciences (WVE) - Sotuvning operatsion rentabelligi|Maze Therapeutics, Inc. - Operatsion marja|Operatsion faoliyat rentabelligi Sionna Therapeutics, Inc. SION|Prime Medicine Bio (PRME) - Operatsion rentabellik|TSHA: Operatsion foyda koeffitsiyenti|Operatsion rentabellik uniQure Pharma|MGTX - Operatsion foyda bo'yicha marjinallik|Operatsion marja RGNX|Operatsion rentabellik SLDB (Solid Biosciences)|Ocugen Corp - Sotuvning operatsion marjasi|PACB: Operatsion foyda bo'yicha sotuv rentabelligi|benitec.com - Operatsion marja|DSGN - Operatsion marja|RCKT: Operatsion marja|FDMT (4D Molecular Therapeutics Inc) - Operatsion rentabellik|Sotuvning operatsion marjasi LXEO|Operatsion rentabellik KRRO|Operatsion marja EDIT|SLN - Sotuvning operatsion rentabelligi|Operatsion marja PRQR (ProQR)|SGMO: Operatsion foyda bo'yicha sotuv rentabelligi|Nautilus Biotechnology - Operatsion marja|Operatsion foyda normasi MGX (Metagenomi, Inc)|DTIL: Operatsion marja|GBIO: Operatsion foyda koeffitsiyenti|Operatsion rentabellik Boundless Bio Inc.|Sotuvning operatsion marjasi Exicure (XCUR)|Operatsion marja IMNN|PHIO (Phio Pharmaceuticals Corp.) - Operatsion foyda normasi|Mustang Bio, Inc. - Sotuvning operatsion marjasi|RNAZ - Sotuvning operatsion marjasi|BNGO: Sotuvning operatsion marjasi|APDN (Applied DNA Sciences Inc) - Operatsion foyda bo'yicha sotuv rentabelligi|BLUE (Bluebird Bio) - Sotuvning operatsion marjasi|ImmunoPrecise Antibodies Ltd - Operatsion foyda normasi|OMGA (Omega Therapeutics Inc) - Operatsion marja|Operatsion rentabellik OMIC|Operatsion rentabellik Regulus Therapeutics Inc. (RGLS)|Sotuvning operatsion marjasi Syros Pharmaceuticals, Inc. SYRS|Telesis Bio - Sotuvning operatsion marjasi|Operatsion foyda normasi TCON|UBX - Operatsion rentabellik